| Sian Rankin, LCSW | |
|
151 N Main St, Decatur, IL 62523-1206 | |
| (217) 362-6262 | |
| Not Available |
| Full Name | Sian Rankin |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 151 N Main St, Decatur, Illinois |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295432078 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | (* (Not Available)) | Primary |
| Entity Name | Heritage Behavioral Health Center, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639231731 PECOS PAC ID: 0547208951 Enrollment ID: O20050418000456 |
News Archive
Combining partially differentiated stem cells with gene therapy can promote the growth of new "insulation" around nerve fibers in the damaged spinal cords of rats, a new study shows.
Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).
Boehringer Ingelheim, working with pharmaphorum media, has brought together patients, patient groups and globally renowned clinicians to launch a report into IPF entitled Inspiration - a new initiative dedicated to raising awareness of IPF,1 a rare disease that is relatively unheard of, frequently misdiagnosed and little understood.
The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.
ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sian Rankin, LCSW 151 N Main St, Decatur, IL 62523-1206 Ph: (217) 362-6262 | Sian Rankin, LCSW 151 N Main St, Decatur, IL 62523-1206 Ph: (217) 362-6262 |
News Archive
Combining partially differentiated stem cells with gene therapy can promote the growth of new "insulation" around nerve fibers in the damaged spinal cords of rats, a new study shows.
Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).
Boehringer Ingelheim, working with pharmaphorum media, has brought together patients, patient groups and globally renowned clinicians to launch a report into IPF entitled Inspiration - a new initiative dedicated to raising awareness of IPF,1 a rare disease that is relatively unheard of, frequently misdiagnosed and little understood.
The anti-inflammatory drug celecoxib, known by the brand name Celebrex, triggers liver cancer cell death by reacting with a protein in a way that makes those cells commit suicide, according to a new study.
ZymoGenetics, Inc. announced that final progression-free survival results will be presented from a Phase 2 clinical trial in patients with Stage 4 metastatic melanoma at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 5, 2010 in an oral presentation. The open-label multi-center clinical trial evaluated 3 dose regimens of Interleukin 21 (IL-21) in 40 patients with no prior systemic therapy for metastatic melanoma.
› Verified 7 days ago
Mr. Charles Russell Kerwin, LCSW, CADC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1770 Elake Shore Dr, Decatur, IL 62521 Phone: 217-428-1900 | |
Mrs. Leesa K Reed, MSW, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 151 N. Main St., Heritage Behavioral Health, Decatur, IL 62523 Phone: 217-362-6262 | |
Nicole Lynn Ekiss, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1170 E Riverside Ave, Decatur, IL 62521 Phone: 217-387-3625 | |
Susan S Brinklow, LCSW, ACSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 3040 N University Ave Ste 2, Decatur, IL 62526 Phone: 217-872-1700 Fax: 217-872-1366 | |
Jaymie L Mccammon, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 106 N Main St, Decatur, IL 62523 Phone: 779-220-0441 | |
Adrian Marie Byrd, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 5130 Hickory Point Frontage Rd Ste 219, Decatur, IL 62526 Phone: 217-358-4548 Fax: 217-706-5779 | |
Tara Ulis, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 102 W Kenwood Ave Ste 120a, Decatur, IL 62526 Phone: 217-520-1047 |